GET DAILY SIGNALSPrecision BioSciences (DTIL) Narrows Q3 Loss While Advancing Key Gene-Editing Programs
Key Takeaways
- Precision BioSciences reported a third-quarter net loss of $7.6 million, or $(0.28) per share, sharply narrower than the $21.8 million, or $(1.84) per share, loss a year earlier.
- Loss per share of $(0.28) beat the consensus estimate of roughly $(0.84), driven in part by a non-cash warrant liability fair-value gain.
- No revenue was reported for the quarter ended September 30, 2026, consistent with the company's clinical-stage status and below modest consensus estimates.
- Cash, cash equivalents, and restricted cash totaled about $108.0 million, which management expects to fund operations through 2028 and key clinical milestones.
- The company advanced its two lead programs, PBGENE-HBV and PBGENE-DMD, including dosing the first patient in the Phase 1/2 FUNCTION-DMD study.
- For additional context on this ticker, explore Major News, Today's Price Move, Price Targets, and Forecast on dedicated pages.
- For broader market ideas and signals, consider exploring Trending AI Robots to discover AI-driven trading strategies.
Why Quarterly Results Matter for a Clinical-Stage Biotech
Precision BioSciences operates as a clinical-stage gene editing firm, so its earnings updates focus more on pipeline progress and cash management than on any top-line sales. The company is developing two wholly owned candidates using its ARCUS platform: PBGENE-HBV targeting chronic hepatitis B and PBGENE-DMD for Duchenne muscular dystrophy. With no commercial products yet, investors track these reports for signs of clinical advancement, spending control, and runway that can support ongoing trials without immediate equity raises. This quarter’s update is notable because it indicates the firm is holding to timelines for upcoming data while keeping its balance sheet intact.
Third-Quarter Financial Details
For the period ended September 30, 2026, DTIL posted a net loss of $7.6 million, or $(0.28) per share on both a basic and diluted basis, compared with a $21.8 million loss, or $(1.84) per share, in the year-ago quarter. The per-share result exceeded the consensus estimate of approximately $(0.84). Most of the improvement came from $12.8 million in other income, driven by a non-cash gain tied to the fair-value adjustment of warrant liabilities; this item does not impact operating cash flow. Revenue remained at zero, versus less than $0.1 million the prior year from a legacy Novartis collaboration. Research and development costs fell to $12.7 million from $13.4 million, while general and administrative expenses edged up to $7.7 million from $7.3 million. Cash, cash equivalents, and restricted cash stood at roughly $108.0 million at quarter-end.
Market Reaction and Clinical Narrative
Because DTIL generates no revenue, price moves around earnings tend to reflect clinical momentum and balance-sheet strength more than any financial headline. A narrower loss and extended cash runway generally register as positive, though the non-cash nature of part of the improvement and the lack of sales may limit enthusiasm. Investors are also evaluating the first-patient dosing in the PBGENE-DMD study against the usual risks that trial outcomes could disappoint. Sentiment before the report centered on whether the company could sustain progress toward year-end data releases.
What to Watch Going Forward
Future performance for DTIL will be driven by clinical readouts rather than quarterly revenue. Management expects data updates from both the PBGENE-HBV and PBGENE-DMD programs by the end of the year. A late-breaking oral presentation from the ELIMINATE-B trial in hepatitis B is set for November 8 at The Liver Meeting 2026, with the abstract scheduled for release on November 5. Key items to monitor include signs of durable viral response in the hepatitis B program and initial safety and activity signals from the Duchenne study. The cash position through 2028 lowers near-term financing pressure, yet the company could still turn to its at-the-market facility if timelines extend. Continued R&D discipline will help stretch the existing balance, but as a clinical-stage biotech, DTIL remains subject to binary outcomes from trial results that can move the stock sharply.
Using AI Tools in My Research Process
I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. It helps surface ideas based on technical patterns and fundamentals without having to build every screen from scratch.
Exploring Tickeron’s AI Tools for Biotech Analysis
In my own workflow, I occasionally turn to Tickeron’s AI Screener when reviewing clinical-stage names like DTIL. The tool lets me apply filters for sector, market cap, and technical signals in one place, which can highlight comparable opportunities or confirm relative strength. It is not a trading system on its own, but it serves as a useful starting point for deeper fundamental review.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DTIL saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for DTIL moved out of overbought territory on November 02, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 49 similar instances where the indicator exited the overbought zone. In 46 of the 49 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DTIL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
DTIL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for DTIL entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on DTIL as a result. In 61 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for DTIL just turned positive on October 19, 2026. Looking at past instances where DTIL's MACD turned positive, the stock continued to rise in 30 of 44 cases over the following month. The odds of a continued upward trend are 68%.
DTIL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for DTIL crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 70%.
Following a +16.54% 3-day Advance, the price is estimated to grow further. Considering data from situations where DTIL advanced for three days, in 189 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.248) is normal, around the industry mean (3.104). P/E Ratio (-5.576) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (2.997) is also within normal values, averaging (439.647).
The Tickeron PE Growth Rating for this company is 39 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. DTIL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DTIL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of technology to produce custom, genome-editing enzymes for human health and biological research
Industry Biotechnology
Advertisement